Business context and reporting period
Amgen Inc. is a biotechnology company focused on human therapeutics and reports as one business segment. This unaudited Form 10-Q covers the quarter and six months ended June 30, 2019; comparisons are with the corresponding 2018 periods. Amounts are in U.S. dollars.
Key financial metrics
| Metric | Q2 2019 | Q2 2018 | Six months 2019 | Six months 2018 |
|---|---|---|---|---|
| Total revenue | $5.871B | $6.059B | $11.428B | $11.613B |
| Operating income | $2.678B | $2.832B | $5.150B | $5.558B |
| Net income | $2.179B | $2.296B | $4.171B | $4.607B |
| Diluted EPS | $3.57 | $3.48 | $6.75 | $6.73 |
| Operating margin | 45.6% | 46.7% | 45.1% | 47.9% |
| Net cash from operations | Not provided for quarter | Not provided for quarter | $3.259B | $4.829B |
Q2 cost of sales was 17.2% of revenue versus 16.9% a year earlier; R&D was $924M, up 6%, and SG&A was $1.260B, down 7%. The six-month effective tax rate was 14.5%, compared with 12.5%.
At June 30, cash, cash equivalents and marketable securities totaled $21.758B; current assets were $30.746B against current liabilities of $10.622B. Total debt carrying value was $30.614B, including $2.816B current and $27.798B long-term, down from $33.929B at year-end 2018. The company had $10.794B in stockholders’ equity. Six-month investing cash flow was $6.300B, principally reflecting net inflows from marketable securities; financing cash outflow was $10.979B, including $5.447B of share repurchases, $3.650B of debt repayment and $1.781B of dividends.
Material changes versus prior period
- Q2 revenue declined 3% and net income declined 5%; six-month revenue declined 2% and net income declined 9%. Q2 diluted EPS rose 3% despite lower net income, supported by an 8% reduction in diluted shares, principally from buybacks. Six-month diluted EPS was nearly flat.
- U.S. product sales fell 5% in Q2, while rest-of-world sales rose 9%. Management attributed overall product-sales pressure mainly to lower net selling prices, partly offset by stronger unit demand.
- Product trends were mixed: Q2 Neulasta sales fell 25%, Sensipar/Mimpara fell 71%, and Aranesp fell 8%; Prolia rose 14%, XGEVA rose 10%, and other products rose 41%. Biosimilar competition and generic launches pressured several established products.
- Six-month R&D expense increased 11% to $1.803B, reflecting increased research and early-pipeline spending, particularly in oncology. Operating cash flow fell by $1.570B year over year, primarily due to higher IRS-related payments, sales deductions paid to customers and lower net income.
Outlook, commentary, risks and unusual items
- Management expected lower net selling prices in the remainder of 2019 versus 2018 and said product mix would continue to negatively affect cost of sales. The filing estimates 2019 capital project spending of approximately $700M; it provides no clear full-year revenue or EPS guidance in the supplied text.
- Management intends to continue investing in the business while returning capital through dividends and repurchases. The board added $5.0B to the repurchase authorization in May; $4.7B remained available at June 30. The quarterly dividend was $1.45 per share.
- Significant risks include pricing and reimbursement pressure; biosimilar and generic competition; and legal disputes. Amgen reported an IRS Revenue Agent Report proposing substantial adjustments for 2010–2012, primarily involving U.S.-Puerto Rico profit allocation. The matter is in administrative appeals, is not expected to be resolved within 12 months, and could materially affect financial statements.
- The company identified manufacturing exposure to Puerto Rico’s utility, infrastructure and political conditions, as well as cybersecurity and third-party vendor risks. It reported a June 2019 cyberattack at a vendor and a several-week disconnection of systems, but said the event had not had a material adverse effect.
- Unusual or notable items included Hurricane Maria insurance proceeds benefiting cost of sales, though the amount was not specified here; a $98M U.S. government Neulasta order in Q1; and the prior-year tax benefit that contributed to the higher 2019 effective tax rate.
- Pipeline and commercial developments included U.S. launches of biosimilars KANJINTI and MVASI in July 2019; a negative European committee opinion on EVENITY, for which a reexamination was requested; and discontinuation of the CNP520 Alzheimer’s prevention program. These developments occurred after quarter-end where noted.
Investor verification priorities
- Track net pricing, unit demand and competitive erosion for Neulasta, Sensipar, EPOGEN, Aranesp and ENBREL, and the sales contribution from newer products and biosimilars.
- Review the IRS dispute, unrecognized tax benefits and remaining $6.2B of scheduled repatriation-tax payments.
- Assess cash generation against debt maturities, capital spending, dividends and the pace of share repurchases.
- Monitor patent and antitrust litigation outcomes, including biosimilar launch challenges and Sensipar-related matters; potential losses are not quantified clearly in the filing.
- Evaluate exposure to drug-pricing and reimbursement policy changes, and operational resilience at the Puerto Rico manufacturing site and key vendors.